<DOC>
	<DOC>NCT00443534</DOC>
	<brief_summary>This protocol allows subjects who have participated in a previous SU011248 protocol the ability to continue to receive SU011248 after their study has ended.</brief_summary>
	<brief_title>A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.</brief_title>
	<detailed_description />
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Participation in a previous SU011248 protocol and are judged by the investigator to have the potential to derive clinical benefit by remaining on SU011248 after the prior protocol ends. Severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>